Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abilify for Stimulant-Resistant ADHD in Children
NCT00279409Phase 2Terminated
- Sponsor
- New York State Psychiatric Institute
- Start
- Jul 2006
- Primary completion
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aripiprazole in attention deficit hyperactivity disorder (ADHD), sponsored by New York State Psychiatric Institute. Primary endpoint: Attention Deficit Hyperactivity Disorder Rating Scale IV. Started Jul 2006; status: terminated.
02
Drugs
aripiprazole
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00279409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00279409.